Furthermore, the same research unit recently demonstrated that anti-CD38-CAR-T cells can abrogate aggressive and chemo-resistant subtypes of DLBCL, such as double hit lymphoma (DHL) and double expressor lymphoma (DEL) cells. The gene discussed is CD38; the disease is diffuse large B-cell lymphoma.